Though no statistical analysis was done and values were somewhat similar, canagliflozin showed improvement in HbA1c (-0.6%), FBG (-0.2 mg/L), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) scores (-0.5), C-Reactive Protein (CRP) (-0.9 mmol/L), subcutaneous adipose tissue (-1.1 cm2), visceral adipose tissue (-5.0 cm2), and nitric oxide levels (+ 2.3 umol/L) compared to metformin [40]. The gene discussed is CRP; the disease is Insulin resistance.